source
- GSK to acquire cancer-focused biotech Nuvalent for $10.6 billionGSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
- GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA reviewGSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…